THACI, Diamant, PINTER, Andreas, SEBASTIAN, Michael, TERMEER, Christian C., STICHERLING, Michael, GERDES, Sascha, WEGNER, Sven, KRAMPE, Stefanie, BARTZ, Holger, RAUSCH, Christian, MENSCH, Alexander und EYERICH, Kilian, 2021. Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS). Freiburg: Universität.

Thaci, D., Pinter, A., Sebastian, M., Termeer, C.C., Sticherling, M., Gerdes, S., Wegner, S., Krampe, S., Bartz, H., Rausch, C., Mensch, A., Eyerich, K., 2021. Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS). Universität, Freiburg. https://doi.org/10.1111/bjd.18696

Thaci, D., Pinter, A., Sebastian, M., Termeer, C. C., Sticherling, M., Gerdes, S., Wegner, S., Krampe, S., Bartz, H., Rausch, C., Mensch, A., & Eyerich, K. (ca. 2021). Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS) [Cd]. Universität. https://doi.org/10.1111/bjd.18696

Thaci D, Pinter A, Sebastian M, Termeer CC, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K (2021) Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS). Universität, Freiburg

Thaci, Diamant/ Pinter, Andreas/ Sebastian, Michael/ Termeer, Christian C./ Sticherling, Michael/ Gerdes, Sascha/ Wegner, Sven/ Krampe, Stefanie/ Bartz, Holger/ Rausch, Christian/ Mensch, Alexander/ Eyerich, Kilian, Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS), Freiburg 2021.